Skip to main content

Medprin Biotech

ApplicationFrankfurt, GermanyFounded 2008· One of 381 Application companies tracked by AMPulse

Develops and manufactures regenerative implantable medical devices using biological 3D printing and nano-bionics technology for human tissue recovery, replacement, and regeneration.

CEO / Founder
Yuyu Yuan
Team Size
11-50
Stage
Active
Total Funding
$35M
Latest Round
Post-IPO
Key Investors
Public Investors; 基石资本; 粤科母基金; 国寿股权; 斐君资本; 涌平投资; 北京领瑞

Technology & Products

Key Products

ReDura™ Synthetic Dural Substitute, NeoDura™ Novel Dural Patch, Recranio™ Cranio-Maxillofacial repair system, StypCel™ Absorbable Hemostat.

Technological Advantage

Proprietary biological 3D printing process enables precise fabrication of patient-specific regenerative implants, protected by extensive patent portfolio (85 patents granted, 225 applications).

Differentiation

Value Proposition

Reduces surgical complications and improves patient outcomes through precision-engineered, patient-specific implantable devices that promote tissue regeneration, with CE-marked products sold in over 70 countries.

How They Differentiate

Focuses exclusively on regenerative implantable devices using biological 3D printing, unlike competitors' broader medical device portfolios; offers patient-specific customization through additive manufacturing vs. standard off-the-shelf products.

Market & Competition

Target Customers

Hospitals, healthcare providers, medical device distributors

Industry Verticals

Medical Device; Healthcare; Regenerative Medicine

Competitors

Baxter International Inc., Boston Scientific, Cook Medical, NeuraMedica, Allevi.

Growth & Milestones

Growth Metrics

Products sold to more than 70 countries and regions; over 300 patent applications worldwide and 150 patents authorized; 1,229 LinkedIn followers

Major Milestones

Founded in 2008; CE-marked products sold in over 70 countries; 85 patents authorized; 225 patent applications worldwide

Notable Customers

Medprin's products are sold in over 100 countries and have benefited more than 1,600,000 patients.

https://www.medprin.cn

Why this company matters

Medprin Biotech GmbH occupies a focused niche within regenerative medicine: patient-specific implantable devices fabricated via biological 3D printing and nano-bionics. Unlike large medical device companies that offer broad portfolios of off-the-shelf products, Medprin concentrates exclusively on synthetic implants designed to promote tissue regeneration, targeting cranial, dural, and hemostatic applications.

The company's core technology is a proprietary bioprinting process that enables precise fabrication of patient-matched implants. Key products include ReDura, a synthetic dural substitute; NeoDura, a novel dural patch; Recranio, a cranio-maxillofacial repair system; and StypCel, an absorbable hemostat. These devices are CE-marked and sold through distributors such as Novatec Healthcare, with a reported reach of over 70 countries and more than 1.6 million patients treated.

Medprin's strategic moat rests on its patent portfolio, which it describes as encompassing 85 authorized patents and 225 applications worldwide. The company has raised $35 million from public investors and maintains a team of 11-50 employees. Its primary competitive risk comes from larger medical device incumbents such as Baxter, Boston Scientific, and Cook Medical, which have deeper resources but lack Medprin's dedicated focus on bioprinted regenerative implants.